Telesis Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	27.51	27.44	11.04	6.58	4.81
Revenue Growth (YoY)	0.27%	148.44%	67.93%	36.86%	-
Cost of Revenue	10.56	11.84	6.74	2.95	2.68
Gross Profit	16.95	15.6	4.3	3.63	2.13
Selling, General & Admin	34.6	38.62	25.21	11.06	5.79
Research & Development	17.5	23.46	14.47	8.93	3.32
Other Operating Expenses	11.39	0	0.06	0.07	0
Operating Expenses	63.49	62.08	39.74	20.06	9.1
Operating Income	-46.54	-46.49	-35.44	-16.44	-6.98
Interest Expense / Income	3.11	1.96	1.37	0.69	1.49
Other Expense / Income	-1.94	0.01	2.14	0.88	-0.16
Pretax Income	-47.7	-48.45	-38.94	-18.01	-8.3
Income Tax	0.02	0.02	0.01	0.01	0
Net Income	-47.72	-48.47	-38.96	-18.01	-8.3
Preferred Dividends	1.3	0	0	0	0
Net Income Common	-49.02	-48.47	-38.96	-18.01	-8.3
Shares Outstanding (Basic)	2	2	1	0	1
Shares Outstanding (Diluted)	2	2	1	0	1
Shares Change	1.31%	61.69%	264.34%	-66.66%	-
EPS (Basic)	-29.52	-29.70	-38.52	-64.80	-9.90
EPS (Diluted)	-29.52	-29.70	-38.52	-64.80	-9.90
Free Cash Flow	-36.63	-43.18	-38.55	-15.59	-6.47
Free Cash Flow Per Share	-22.09	-26.38	-38.08	-56.09	-7.76
Gross Margin	61.62%	56.84%	38.93%	55.12%	44.29%
Operating Margin	-169.18%	-169.44%	-320.89%	-249.92%	-145.18%
Profit Margin	-178.21%	-176.68%	-352.78%	-273.87%	-172.78%
Free Cash Flow Margin	-133.16%	-157.40%	-349.11%	-237.00%	-134.63%
EBITDA	-40.49	-43.62	-36	-15.86	-5.96
EBITDA Margin	-147.20%	-158.98%	-326.01%	-241.15%	-123.93%
Depreciation & Amortization	4.1	2.88	1.57	1.46	0.86
EBIT	-44.6	-46.49	-37.58	-17.32	-6.81
EBIT Margin	-162.11%	-169.46%	-340.26%	-263.31%	-141.77%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).